-
July 12, 2011
FDA proposes targeted drug testing guidelines
WASHINGTON (Reuters) - Targeted drugs or therapies up for U.S. regulatory approval would have to be reviewed simultaneously with the diagnostic devices they rely on, according to a proposed policy issued on Tuesday.
-
June 3, 2011
Roche's Tarceva helps lung cancer patients
ZURICH (Reuters) - Roche Holding AG's cancer drug Tarceva nearly doubles the time patients with a distinct type of lung cancer live without their disease getting worse, a late-stage trial showed on Friday.
-
March 21, 2011
Counting lung cancer cells helps predict disease
LONDON (Reuters) - British scientists have found that counting the number of lung cancer cells circulating in a patient's blood could help determine how aggressive the cancer is and predict the best treatment to use.
-
September 28, 2010
Early prostate test study gives hope for accuracy
LONDON (Reuters) - British scientists say they have developed a lab test that can accurately distinguish prostate cancer from healthy tissue and other prostate conditions -- a finding that may in future help men avoid unnecessary treatment.
-
July 20, 2010
New study backs Avastin in lung cancer
LONDON (Reuters) - The drug Avastin won a renewed endorsement as a treatment for lung cancer on Tuesday from a clinical study looking at the drug's use in a broad, real-life setting.
-
September 21, 2009
Hormone therapy may up risk of dying of lung cancer
NEW YORK (Reuters Health) - Among women who already have lung cancer, hormone replacement therapy - which has been tied to a higher risk of serious conditions including breast cancer and heart attacks - seems to increase the risk of death from the tumor, according to a new study.
-
August 20, 2009
Tests help lung cancer drugs reach right patients
CHICAGO (Reuters) - Diagnostic tests that look for specific genetic or molecular characteristics may be the key to helping doctors decide which lung cancer treatments work best for patients, two studies released Wednesday suggest.
-
August 4, 2009
Blood test may diagnose lung cancer, company says
WASHINGTON, Aug 4 (Reuters) - A blood test that detects nine compounds in blood may offer a safe way to diagnose early cases of lung cancer, Celera Corporation reported on Tuesday.
-
July 23, 2009
Cancer meeting reports often not the final word
NEW YORK (Reuters Health) - Preliminary results of cancer treatment studies presented at major cancer meetings should be viewed with caution, because the final results may wind up being quite different, new research shows.
-
July 1, 2009
Europe approves AstraZeneca lung cancer drug
LONDON (Reuters) - AstraZeneca's once-daily cancer pill Iressa (gefitinib) has been approved for certain lung cancer patients in Europe, reviving the fortunes of a product that had until recently been largely written off by industry analysts.
-
June 26, 2009
Psychiatric symptoms can be first sign of cancer
NEW YORK (Reuters Health) - New research suggests that for some patients with cancer, especially brain tumors and small-cell-lung cancer, the first manifestation is a psychiatric symptom.
-
June 1, 2009
Drug keeps lung cancer from worsening: study
ORLANDO, Florida (Reuters) - A drug called Zactima, which failed two earlier trials, was shown in a pivotal study to extend the amount of time patients survived without their lung cancer worsening, researchers said on Saturday.
-
June 1, 2009
Hormone therapy lifts lung cancer death risk: study
ORLANDO, Florida (Reuters) - Use of menopausal hormone-replacement therapy increases the risk of death from lung cancer by 60 percent after five years, U.S. researchers reported on Saturday.
-
June 1, 2009
Drug helps lung cancer patients live longer
NEW YORK (Reuters) - The use of Eli Lilly and Co's Alimta following successful chemotherapy treatment helped patients with advanced lung cancer live significantly longer, according to data released on Saturday.
-
May 21, 2009
Stereotactic radiation treatment slows lung cancer
NEW YORK (Reuters Health) - Stereotactic body radiotherapy, in which beams of radiation are focussed on a tumor, appears to be highly effective for treating certain patients with a common type of lung cancer, Scandinavian researchers report.
-
March 26, 2009
Carotenoid supplements tied to lung cancer risk
NEW YORK (Reuters Health) - Based on the findings from a new study, it appears that people who take higher than recommended doses of carotenoid supplements hoping to keep from getting sick, may actually be doing themselves harm. The long-term use of beta-carotene, retinol, and lutein supplements at doses higher than in multivitamins, increases lung cancer risk, especially in smokers and former smokers, according to investigators from the Vitamins and Lifestyle (VITAL) study.
-
March 19, 2009
Roche files Tarceva for first-line lung cancer use
ZURICH (Reuters) - Swiss drugmaker Roche Holding AG said on Thursday it had submitted its Tarceva drug to the European Medicines Agency for use as a first-line treatment for patients with advanced non-small-cell lung cancer.
-
November 12, 2008
CT lung cancer screening offers pros and cons
NEW YORK (Reuters Health) - New research indicates that while low-dose CT of the chest can identify lung cancers at an early, more treatable stage, it can also lead to unnecessary major surgery that detects no cancer.
-
November 10, 2008
Country star Merle Haggard battling lung cancer
LOS ANGELES (Reuters) - Country singer Merle Haggard, recently diagnosed with lung cancer, had part of a lung removed and is recovering at home, his spokeswoman said on Sunday.
-
October 23, 2008
Gene study turns up 26 lung cancer genes
CHICAGO (Reuters) - A broad analysis of genes has turned up 26 mutations linked with the most common form of lung cancer, several of which play a role in other cancers as well, researchers said on Wednesday.
-
October 10, 2008
Lung cancer in non-smokers a separate disease
NEW YORK (Reuters Health) - Japanese investigators say that survival rates are better for patients with non-small cell lung cancer (NSCLC) who never smoked than in NSCLC patients with a history of smoking. Other disease characteristics are different as well between the two populations.
-
October 6, 2008
Drug combo doesn't boost lung cancer survival
ZURICH/LONDON (Reuters) - Roche Holding AG and Genentech Inc said on Monday a study of the benefits of combining their Tarceva and Avastin drugs for lung cancer patients did not show an increase in overall survival.
-
September 29, 2008
Lilly's Alimta OK'd as front-line lung cancer drug
BOSTON (Reuters) - Eli Lilly and Co on Monday said it has won U.S. approval for its drug Alimta as a first-line treatment for patients with advanced lung cancer.
-
September 15, 2008
Avastin slows progression of lung cancer
ZURICH/LONDON (Reuters) - The results of a study presented on Monday show that Avastin combined with gemcitabine-cisplatin chemotherapy improves the time lung cancer patients live without progression of the disease, according to Swiss drugmaker Roche. There was also a positive trend to extended survival.
-
July 18, 2008
Bone drug has benefits in cancer patients
NEW YORK (Reuters Health) - The bone-strengthening drug zoledronic acid not only reduces fracture risk in patients with cancer that has spread to the bones, it also improves overall survival, according to the results of a retrospective analysis of three large studies.
-
July 3, 2008
Doctors extract cancer cells from blood sample
BOSTON (Reuters) - An experimental process that snags lung cancer cells from a blood sample could give doctors real-time feedback on the most effective therapy, researchers reported on Wednesday.
-
June 2, 2008
Erbitux adds 5 weeks to lung cancer survival
CHICAGO (Reuters) - Lung cancer patients treated in a large clinical trial with ImClone Systems Inc's Erbitux and chemotherapy lived about five weeks longer than patients treated with chemotherapy alone, according to study results released on Saturday.
-
May 16, 2008
Lung cancer patients may live longer with Alimta
WASHINGTON (Reuters Life!) - Adding a little extra chemotherapy after finishing the initial course helped advanced lung cancer patients live longer without having their tumors grow or come back, researchers reported on Thursday.
-
March 13, 2008
Study shows way to predict lung cancer recurrence
WASHINGTON (Reuters) - It may be possible to predict whose lung cancer is likely to come back after surgery has apparently cured it, U.S. researchers reported on Wednesday.
-
February 27, 2008
Experimental lung cancer drug fails clinical trial
LONDON (Reuters) - AstraZeneca Plc is stopping a clinical trial of Recentin as a treatment for lung cancer after a mid-stage study failed to meet its main goal, although trials in colorectal cancer will move ahead.
-
February 18, 2008
Bayer stops late-stage Nexavar trial
BANGALORE (Reuters) - Bayer HealthCare, a U.S. based unit of Bayer AG, said it stopped a late-stage trial of Nexavar in patients with non-small cell lung cancer, after an independent data monitoring committee concluded that the study would not meet its main goal of improved overall survival.
-
January 30, 2008
Nexavar shows promise in acute myeloid leukemia
CHICAGO (Reuters) - The kidney cancer pill Nexava, know generically as sorafenib, has shown promise in treating a small number of people with a type of blood cancer known as acute myeloid leukemia, or AML, U.S. researchers said on Tuesday.
-
January 30, 2008
Lung cancer surgery improves quality of life
NEW YORK (Reuters Health) - Surgery for lung cancer can have a substantial impact on long-term, health-related quality of life, the results of a study published in the current issue of the Journal of Clinical Oncology suggest.
-
January 22, 2008
Nexavar significantly boosts hypertension risk: study
LONDON (Reuters) - Bayer AG and Onyx Pharmaceutical Inc.'s key cancer drug Nexavar significantly raises the risk of high blood pressure, U.S. researchers said on Tuesday.
-
November 27, 2007
PET scans can help lung cancer diagnosis - study
WASHINGTON (Reuters) - The use of positron emission tomography, known as PET scans, can improve the diagnosis of people with lung cancer and better guide treatment decisions, Canadian researchers said on Tuesday.
-
September 5, 2007
Antisoma says lung cancer drug improves survival
LONDON (Reuters) - British cancer specialist Antisoma said on Wednesday that an intermediate phase II clinical trial confirmed that its biggest drug hope, ASA404, could help lung cancer patients to live for longer.
-
August 31, 2007
AIDS drug shows potential as weapon against cancer
WASHINGTON (Reuters) - A drug used to treat people infected with the AIDS virus has shown promise as a possible future weapon against cancer, U.S. researchers said on Friday.
-
August 24, 2007
EU approves Avastin for lung cancer: Roche
ZURICH (Reuters) - The European Union has approved Avastin (Roche Holding AG) to treat patients with advanced non-small-cell lung cancer, the Swiss drugmaker said on Friday.
-
August 22, 2007
UK's NICE upholds block on lung cancer drug
LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog said on Wednesday that pemetrexed, sold by Eli Lilly and Co. under the trade name Alimta, would not be recommended as a treatment for lung cancer on the state health service.
-
July 26, 2007
Added chemotherapy improves lung cancer survival
NEW YORK (Reuters Health) - A course of chemotherapy prior to standard treatment, known as "induction" chemotherapy, appears to improve survival in patients with advanced non-small-cell lung cancer (NSCLC), the most common type of lung cancer, according to a report in the International Journal of Radiation Oncology*Biology*Physics.
-
July 18, 2007
Lung cancer prognosis better for non-smokers
NEW YORK (Reuters Health) - Cigarette smokers who develop non-small-cell lung cancer, the most common type of lung cancer, have a less favorable outlook than do their counterparts who have never smoked, researchers report in the July issue of Chest.
-
July 13, 2007
New breath test detects lung cancer
NEW YORK (Reuters Health) - Testing exhaled breath with a small sensor array can detect lung cancer with moderate accuracy, researchers report.
-
June 4, 2007
Shark cartilage of no benefit to in lung cancer
CHICAGO (Reuters Health) - The addition of the shark cartilage extract "Neovastat" to standard chemotherapy and radiation does not improve survival in patients with non-small-cell lung cancer (NSCLC), according to results of a large multicenter study reported Saturday at the 43rd annual meeting of the American Society of Clinical Oncology.
-
June 4, 2007
Brain radiation increases lung cancer survival
CHICAGO (Reuters Health) - Preventive radiation to the brain significantly reduces the risk of lung cancer spreading to this organ and improves survival, according to data presented in a session Monday at the 43rd annual meeting of the American Society of Clinical Oncology.
-
March 9, 2007
UK's NICE rejects costly Roche lung cancer pill
LONDON (Reuters) - Roche's once-a-day lung cancer pill Tarceva is of limited use and too expensive to be given on the state health service, Britain's main cost-effectiveness watchdog said on Friday.